Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Optimi Health completed its third commercial shipment of 5mg psilocybin capsules to Australia, exporting 1,000 capsules for treatment-resistant depression patients. The company reports no serious adverse events since the September 2025 launch and notes expanding reimbursement coverage from both private and public insurers in Australia.
SRx Health Solutions has completed its acquisition of EMJ Crypto Technologies (EMJX) and rebranded as SRX Global Inc. The company is launching an AI-driven platform strategy focused on capital allocation into high-conviction operating companies and assets. The merged entity will be led by Kent Cunningham as CEO and Eric Jackson as President and Head of Asset Management, with initial investments in companies including Astro Capital, Opendoor Technologies, Uber Technologies, and Optimi Health Corp.
Optimi Health Corp. announced the completion of two standardized microdose psilocybin finished drug products at 1mg and 2mg dosages for clinical research organizations. The products offer consistent, validated doses derived from naturally sourced psilocybin, extending Optimi's existing 5mg formulation currently prescribed for treatment-resistant depression in Australia. All production is conducted in-house at Optimi's GMP-compliant facility in British Columbia, Canada.